Replies to post #201647 on Anavex Life Sciences Corp (AVXL)

[plexrec]

Thanks Investor for posting this pdf. !!!!!

[indialong]

Slide 8 has been disclosed before. How can anyone seeing that slide not want to be in this stock? People keep saying the results of the extension study don't count, because there is no placebo group. That's nonsense. The low blood concentration group is the placebo. It's better than placebo. It's an objective measure that the patient/care giver can know nothing about. Slide 8 shows that the blood concentration of A273 correlates positively with improved daily living scores. Out to 148 weeks!

[makemydaze]

Thanks for the presentation link. I really like this data - it shows me that they're trying to find the why part out. Really fits into the personalized medicine idea. A whole new way of health planning for doctors to consider. I'd think healthcare providers would buy into personalized plans since it would set each patient up with a goal.

[Investor2014]

A few thoughts on what was presented:

1) "ANAVEX®2-73-Treated Patients have higher Abundance of Bacteroidetes and Firmicutes Phyla in Gut Microbiota"

Good - Additional biomarker confirmation that the A2-73 treated patients do have AD and thus further helps to eliminate misdiagnosis.

2) "KEM® Identifies Changes in two Gut Microbiome Families - Ruminococcaceae and Porphyromonadaceae - Associated with Response to ANAVEX®2-73"

On the face of it seems meaningful delta ADCS-ADL increase in the High concentration patients with a relative abundance of the two KEM covariant bacteria families identified, but as usual it leaves some unanswered questions, at least in my mind:

- There is an enormous spread in response among the 14 patients (of 16 providing stool samples) especially among the High concentration Delta ADCS-ADL scores. Why - and how does this correlate with the spread in response in the high concentration group excluding the Gut analysis?

- Not sure I understand from this representation the relative importance to response of the two bacteria types?

- Does it mean just as little in terms of meaningful clinical benefit as the SIMGMAR1 and COMT1 variant genes?

- At least for the gene variants we got charts showing that although highly stat sig the outcome difference was minute.

- Why not similar charts for this analysis?

This PM stuff to me seems a bit like fashionable dressing cloaked in a lot of words.